“a favorable trend”

34 Initial results demonstrated immunogenicity of both vaccines but showed no significant survival differences between study arms 34 ; however, post-hoc analysis of long-term clinical outcomes revealed significantly improved OS and a favorable trend to improved RFS with melanoma-cognate helper peptide vaccination, with greatest benefit in males (Table 2 ). 35 These results provide support for designing a randomized phase III trial with melanoma helper peptide vaccination powered to detect differences in clinical outcome and highlights the need to study the impact of biologic sex on outcomes in vaccine trials.

For MACE, no strategy was superior in men, while de-escalation to clopidogrel showed a favorable trend in women.

In the no prior bevacizumab use group, the analysis showed a favorable trend but no significant difference in OS.

Therefore, when these kinds of algae become the dominant species, the nutrient content in the pond would show a favorable trend.

POPular Genetics similarly demonstrated a favorable trend in ischemic and bleeding outcomes with genotype‐guided therapy [ 27 ].

MFC-MRD–free survival showed a favorable trend in the maintenance group, although this did not reach statistical significance (2-year MFC-MRD–free survival: 85.5% [95% CI, 74.4–98.3] vs. 68.7% [95% CI, 57.3–82.4], p = 0.051).

Unsurprisingly, in the overall cohort of 255 patients, no statistically significant differences were observed in disease-free survival (DFS) (HR 0.71, 95% CI 0.48–1.05, p = 0.084) or overall survival (OS) (HR 0.69, 95% CI 0.48–1.05, p = 0.096), although a favorable trend was noted in the surgical arm, suggesting the possibility of a type II error.

Surface to bulk diffusion The DFEs for a Ti i show a favorable trend towards the bulk of rutile TiO 2 .

Regarding overweight patients, a pooled analysis over 5 years of the pivotal phase three clinical studies (reSURFACE 1 and 2) highlighted a favorable trend in term of PASI and DLQI responses of tildrakizumab 200 mg compared with tildrakizumab 100 mg in patients with a body weight ≥90 kg ( 26 ).

Conversely, the FbHg/AgP@Exo group displayed markedly increased collagen deposition, characterized by dense and orderly aligned collagen fibers ( Figure 8 a ; Figure S15 , Supporting Information), indicating a favorable trend for promoting tissue regeneration.

There was a favorable trend in the subpopulation with established CVD compared to those without established CVD.

Although Group CN showed a favorable trend toward a higher disease control rate (100% versus 57.1%), a definitive clinical benefit in terms of PR rate could not be established.

For secondary education, the rates declined from 70.6% in 2003 to 59.7% in 2014, and down to 44% in 2022, showcasing a favorable trend.

Although not statistically significant, the proportion of patients achieving TMPG 3 and cTFC also showed a favorable trend in the IC group compared with that in the IV group (Fig. 1 ).

Conclusions: A favorable trend is observed with respect to the mean LOE as well as the number of level 2 studies and RCTs over time.

Lipid profile and HbA1c A favorable trend with reductions in lipid parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides was observed with norUDCA treatment, HbA1c levels remained relatively stable in both groups.

Interestingly, although not statistically significant, a favorable trend in OS was also seen in the aforementioned studies [ 30 – 32 ].

Here, though not reaching statistical significance, a favorable trend towards empagliflozin was observed regarding left ventricular strain, which was more pronounced in the HFpEF group (adjusted mean treatment difference, 2.18% [SE, 1.16 (95% CI, − 0.28 to 4.64)]; p = 0.08) [ 34 ].

Using univariate analysis, although Group 2 showed a favorable trend in patient survival rates compared with Groups 3 and 4, the statistical significance was weak.

Additionally, while there was a favorable trend toward a reduction in urinary albumin-to-creatinine ratio (UACR) in the ocedurenone group, this change did not reach statistical significance within the study period [ 73 ].

Although there is a favorable trend, thrombopoietic agents did not significantly decrease dose delays and/or reductions compared with placebo or no treatment (21.1% [95% CI: 10.8%, 37.0%] vs 40.4% [95% CI: 9.6%, 81.2%], P = 0.364) ( Fig 2 , Table 2 ).

Despite the lack of statistical significance, this observed reduction reflects a favorable trend toward improved microvascular outcomes with semaglutide and is clinically relevant, as the prevention of microvascular outcomes is a critical concern in the management of T2D.

PT for EBC showed a favorable trend for OS compared with XT, but no clear superiority was observed.

Moreover, there is a favorable trend in AHT group, which may be due to improved reperfusion after thrombolysis.

Constipation outcomes suggested a favorable trend associated with physiotherapy, consistent with evidence linking mobility and physical activation with bowel regulation (Helgesen et al. 2024 ; Cui et al. 2024 ).